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Background: During oncologic surgery, intraoperative manipulation of tumor tissue is almost unpreventable and
causes a high risk of tumor cell dissemination into venous blood. A tumor cell-reducing effect of leukocyte
adhesion filter systems has been shown under in vitro conditions.
Methods: In a first clinical attempt, leukocyte adhesion filters were integrated into veno-venous bypass systems in
four patients undergoing extended liver surgery for secondary hepatic malignancies.
Practicability, handling, and safety aspects as well as potency of cell removal and clinical side effects of the filter
system were analyzed.
Results: All patients tolerated the application of the system without problems during operative and postoperative
follow-up. Immunohistochemical staining of perioperative blood samples detected cytokeratin positive (CK+) cells
in three cases during the hepatic mobilization.
Conclusions: Effectiveness of CK+ cell depletion and safety of the procedure was shown. The presented surgical
technique represents a safe and innovative tool; however, clinical significance has to be examined in a larger
patient cohort.
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In many studies the prognostic relevance of circulating
tumor cells in patients undergoing resection of primary
and metastatic colorectal cancer has been demonstrated
[1,2]. In addition to preoperatively existing circulating
tumor cells, manipulation of tumor tissue during onco-
logic surgery may result in an extra tumor cell release into
the systemic blood circulation. Therefore, intraoperative
surgical manipulation of tumors could influence the prog-
nosis of the underlying malignant diseases [3-5]. A simple
method to prevent such perioperative cell dissemination
in patients with primary colorectal cancer was described
in the 1960’s, the so-called ‘no-touch’ surgery, with early
vascular closure before preparation and resection [6]. In
patients undergoing liver resection for primary or secon-* Correspondence: k.oldhafer@asklepios.com
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reproduction in any medium, provided the ordary malignancies, prevention of intraoperative tumor cell
dissemination is difficult to obtain. The high incidence of
mechanically-induced intraoperative tumor cell dissemin-
ation might be caused by the anatomy and the need of ex-
tensive mobilization before possible occlusion of the
venous drainage [7]. Therefore, surgical attempts such as
the ‘anterior approach’ were developed [8,9]. As surgical
mobilization is unpreventable in most attempts, additional
techniques to reduce the release of tumor cells into the
systemic circulation should be considered. We have previ-
ously shown that cell filtration of blood drained from
veins located close to the tumor could be a useful option
[10]. As shown in previous studies, special filter mediums
used for leukocyte depletion are able to remove tumor
cells under in vitro conditions [11]. Comparable filter sys-
tems are used in cardiac surgery combined with a heart-
lung machine and in blood banks for preparation of stored
blood units [12].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic drawing of the extracorporeal veno-venous
bypass circulation system. Portal, left femoral, and left subclavian
veins are cannulated by flow catheters. A centrifugal bio pump
system (BP80, BioMedicus©, Germany) is used (P). Filter cartouches
(F) are integrated in parallel.
Oldhafer et al. World Journal of Surgical Oncology 2013, 11:159 Page 2 of 7
http://www.wjso.com/content/11/1/159We present a clinical pilot study in four patients suf-
fering from secondary hepatic malignancies. Patients
underwent extended liver surgery with leukocyte deple-
tion filters integrated within the extra corporal veno-
venous bypass system.
Methods
After preclinical testing in a porcine model [13] and ap-
proval of the local ethics committee (Hannover Medical
School) for first clinical investigations, leukocyte adhe-
sion filters (Leukogard LG-6, Pall©, Germany) were inte-
grated into the bypass circuit (bio pump system BP80,
BioMedicus©, Germany) in four patients undergoing ex-
tended liver surgery [14] due to colorectal metastasis
with the need of extracorporeal veno-venous circulation
(Table 1).
Potency of cell removal, clinical side effects and tech-
nical handling of the filter system were analyzed. Patient
follow-up was performed up to 26 months after operation.
Veno-venous bypass
The extracorporeal bypass system was implemented by
puncture of the left subclavian and left femoral vein
using high-flow catheters (14 F, Medos©, Germany) in
the Seldinger technique. After laparotomy and dissection
of the hepatoduodenal ligament the portal vein was add-
itionally cannulated [15]. Leukocyte filters were inte-
grated into the bypass circuit. The tubing system was
pre-coated with 10% albumin-solution. After system
setup, the extracorporeal circulation was started follow-
ing simultaneous clamping of the inferior cava vein be-
neath the diaphragm (Figure 1); the flow rate was kept
between 0.9 and 2.5 L/min. During bypass circulation all
patients received heparin within an activated clotting
time target of >150 s. Each 30 minutes of filtration the
filter cartridges were replaced. Once hepatic mobilization
finished, leukocyte depletion filters were removed for theTable 1 Patient’s characteristics
Case Age/sex Primary Tumor
Location Stage
(UICC, TNM)
1 72/m Colon III
T3N1M0
2 66/f Rectum IV
T3N0M1
3 49/f Colon IV
T3N2M1
4 62/m Rectum IV
T3N2M1
Patient data: localization, UICC, and TMN stage of primary tumor; prior treatment bremaining bypass time (individually depending on the sur-
gical procedure).
Filtration system
LG-6 (Leukogard 6W, Pall corp., NY, USA) is a
leukocyte-depletion arterial blood filter, a latex-free de-
vice, with a polycarbonate surface. The maximum blood
flow filtration rate is 6 L/min. It provides a three-stage
system for gas separation with automatic venting system
and has a 40 μm-pore polyester filter, disposable as a
cartridge. The priming volume for this filter is 220 mL,
with 3/8-inch barbed inlet and outlet ports.
Surgical procedure
Case 1
The 72-year-old patient was suffering from a liver
metastasis located in segment I. The metastasis hadPrior treatment before admission
Surgery CTX RTX
Hemicolectomy left + -
Anterior rectum resection + +
Rectosigmoidectomy + -
Hemihepatectomy right + S III
Metastasectomy S II
Anterior rectum resection + -
Segmentectomy S VII
efore admission: surgery, chemotherapy (CTX), and radiotherapy (RTX).
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hepatic vein (Figure 2). The tumor was only resectable
together along with part of the inferior caval vein and
parts of the liver veins; therefore an ex situ liver resec-
tion was planned. After laparotomy and exclusion of ex-
trahepatic tumor manifestation, the veno-venous bypass
was started after integration of two leukocyte adhesion
filters in all four patients. During the liver mobilization
phase, venous blood was filtrated continuously (in all
four patients) after infradiaphragmal inferior vena cava
(IVC) clamping. After total hepatectomy, a bench resec-
tion of the segments I, IV to VIII, and reconstruction of
the middle and left hepatic vein and the IVC was done
(Figure 3). During the ex vivo surgical procedure, the
liver was perfused in 30 minute intervals through portal
vein and hepatic artery using histidine-tryptophan
-ketoglutarante solution. The auto-transplantations of
the remnant liver followed the techniques applied in ca-
daver liver grafting.Figure 3 A bench resection of segments I, IV to VIII was
performed under ex situ conditions. The inferior vena cava and the
liver veins were reconstructed using parts of the more distal inferior
vena cava which itself was replaced by a Gore-Tex prosthesis.Case 2
The 66-year-old patient was suffering from multiple liver
metastasis located in segments IV, VII, and VIII with
suspected infiltration of the left branch of the portal
vein.Case 3
The 49-year-old patient was suffering from recurrent
liver metastasis located segment IVb with suspected in-
filtration of the portal vein. The patient had already gone
through major liver surgery twice before.Figure 2 CT scan showing the liver metastasis infiltrating the
inferior vena cava and all three liver veins. The tumor was
mainly located in segment I.Case 4
The 62-year-old patient was suffering from recurrent
liver metastasis located in segment VI with suspected in-
filtration of the right branch of the portal vein. He had
already gone through liver segmentectomy before.
Blood sampling and immunohistochemistry
Blood samples for determination of WBC, platelet, free
hemoglobin, and haptoglobin count were taken prior to
operation and during the bypass circulation after 10, 20,
30, 40, 50, and 60 minutes, and on each postoperative
day (POD).
Detection of cytokeratin positive (CK+) cells from ven-
ous blood (sampling prior surgery, during mobilization
of the liver on the bypass and after filter passage, 3×9
mL aliquots) was achieved after FicollW (Pharmacia,
Germany) density gradient centrifugation (669 g, 4°C,
30 minutes) by immunohistochemical labelling with an
anti-cytokeratin antibody and microscopic analysis, regard-
ing cell-morphologic parameters (Epimet-kitW, Micromet,
Germany) [16-18].
Results
An R0 resection was reached in all cases. The mean op-
eration time was 8.2 hours; the mean bypass time was
1.2 hours for the in situ procedures, 6 hours in the ex
situ case; mean filtration time was 39 minutes. The
Figure 5 Polarized light microscopy. Microscopic analysis
(20× magnification) of filter medium showing cytokeratin
positive (CK+) cells.
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tracorporeal circulation in all cases.
No hemolytic reactions were noticed; parameters for
hemolysis as free hemoglobin and haptoglobin remained
within the normal range.
A significant perioperative reduction of the WBC
count after starting filter passage was observed in all
cases. After 30 minutes of filtration, the mean loss of
78% WBC was reached; the lowest value was 1.5 WBC
per μL of blood in one case. The WBC increased to
physiological values in all four cases within 48 hours
after operation. CK+ cells – suspected as malignant cells
– were detected in one case prior to operation, and in
three cases during mobilization of the liver in venous
blood before filter passage (Figure 4).
Case 1
The postoperative course was uneventful. Histology re-
vealed multiple liver metastasis of an adenocarcinoma
and a lymph node metastasis within the falciform liga-
ment. CK+ cells, suspected as malignant cells, were
detected in blood samples taken during mobilization of
the liver and within the filter medium fibers which were
analyzed microscopically (Figure 5). Comparable cells
were not detected in blood samples from the filter out-
flow. The patient was discharged on the 27th POD in a
good general condition. The patient died 22 months
after liver resection due to hepatic tumor recurrence.
Case 2
The postoperative course was uneventful. Histology re-
vealed two metastases of an adenocarcinoma within the
liver (6 and 8 cm∅). CK+ cells were not detected in any
blood sample. The patient was discharged on the 14th
POD. He died 21 months after the operation; 6 months
prior to death pulmonary and cerebral metastases wereFigure 4 The image shows a cytokeratin positive (CK+) cell in
hepatic venous blood (magnification 400×).detected, tumor recurrence within the liver was not
observed.
Case 3
The postoperative course was complicated by cardiopul-
monary insufficiency. CK+ cells were detected in blood
samples taken during mobilization of the liver and
within the filter medium fibers. One suspect cell was
also detected in blood samples from the filter outflow.
The patient died on the 26th POD. Post-mortem ana-
lyzes showed a myocardial infarction and endocarditis.
Case 4
The postoperative course was uneventful. Histology re-
vealed multiple liver metastases of an adenocarcinoma.
CK+ were detected in blood samples taken during
mobilization of the liver and within the filter medium fi-
bers. Comparable cells were not detected in blood sam-
ples from the filter outflow. The patient was discharged
on the 11th POD. The patient is alive and in a good general
condition without signs of tumor recurrence 26 months
after operation.
A detailed summary of surgical procedures and intra-
operative findings is shown in Table 2.
Discussion
Leukocyte depletion filters, used for preparation of
leukocyte-poor red cell or platelet concentrates, have
been evolving continuously [19]. Despite an evident cap-
acity increase in leukocyte removal, most of the mecha-
nisms of cell removal still remain unclear [20]. Multiple
factors seem to be involved. The depletion of WBC is
based on depth-filtration in a fiber-network with a pos-
sible subsequent adhesion to the fibers after activation
[20]. There is evidence for a potential removal capacity
also for malignant cells from whole blood [21]. The
clinical use of leukocyte depletion filters has been
established throughout different clinical disciplines. For
Table 2 Type of resection and perioperative findings
Case Resection Vascular reconstruction Technique LG6 CK + A CK + B CK + C BM
1 I, IV-VIII IVC, Liver veins by IVC patch and Gore-Tex prosthesis Ex situ 47 min - + - nd
2 III, IV-VIII LPV by venous patch In situ 27 min - - - nd
3 IVb RPV by venous patch In situ 23 min + + (+) +
4 V-VIII - In situ 58 min - + - nd
Surgical procedures: resected liver segments, vascular reconstruction (IVC inferior vena cava, LPV left portal vein, RPV right portal vein), technical procedure
(ex or in situ resection), duration of filtration with LG6 filter.
Perioperative findings: cytokeratin positive (CK+) cells within preoperative (A), intraoperative (B) and filter-outflow (C) blood samples; bone marrow (BM) status for
CK+ cells. Nd no data.
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in extracorporeal circulation systems, namely heart-lung
machines for open heart surgery in order to reduce the
ischemic reperfusion injury [12].
In contrast to the regulations for safety of blood prod-
ucts with a need of complete tumor cell depletion in
transfusion medicine, a significant reduction of dissem-
inating tumor cells during resection of tumor tissue in
surgical oncology could indeed be helpful for the patient
[22,23]. Although the characterization of tumor cells
detected intraoperatively is still incomplete, there is evi-
dence for lower survival rates in patients with dissemi-
nated tumor cells [24-26].
The cellular adhesion capacity of a filter medium is
based on its saturation kinetics (Pall Company, manufac-
turer data). In the initial filtration period, a maximum of
cells are removed from the circulating blood, exhausting
filter capacity after approx. 20 minutes of filtration time.
This effect also occurred in our study within the first 30
minutes of filtration time. In all cases, filtration within
the veno-venous bypass up to 58 minutes (using two fil-
ter cartouches) was uneventful. Although a significant
WBC depletion was achieved, critical leucopoenia com-
plicated by postoperative infections was not observed.
For safety reasons, the coagulation cascade should not
be activated during filter medium passage. Gu et al.
could not observe an activation of complement factors
or increasing elastase or thromboxan concentrations in
filter systems using polyester diaphragms [12]. In our
own preclinical animal model [13] and in the presented
cases, no signs of hemolysis were observed.
It remains more or less unclear which mechanisms of
leukocyte depletion filters are involved in consecutive
tumor cell depletion. Apart from the selection of the re-
spective filter medium, the ability for tumor cell deple-
tion also depends on the cell entity. Edelman et al. [23]
proved a tumor cell-depleting effect using isolated tumor
cells of urothelium carcinoma for the leukocyte filter
system RC-400W (Pall, Germany) under in vitro condi-
tions. Perseghin et al. [27] reported a similar clinical ob-
servation in patients with lung carcinoma, filtering cell
saver blood from the surgical site using leukocytedepletion filters. Catling et al. showed, in 50 consecutive
analyzed gyn-oncology patients, that no remaining vi-
able tumor cell could be found after filtration of cell
saver reservoir blood by leukocyte filters [28]. In our
own preclinical work we could state under in vitro
conditions that the leukocyte depletion filters used in
this study reduced the number of native human tumor
cells of colorectal carcinoma from blood-group-com-
patible full blood [11].
However, in our opinion, the liver mobilization phase
carries the highest risk for tumor cell dissemination dur-
ing surgery. During ‘conventional’ hepatic resection,
complete mobilization of the right lobe of the liver, with
the right hepatic vein controlled outside the liver before
parenchymal dissection, has been advised by most sur-
geons. This helps to reduce the amount of surgical blood
loss – unfortunately, it also includes manipulation of the
tumor-bearing parts of the liver. The ‘non-conventional’
anterior liver resection technique is an attempt to avoid
prolonged manipulation of the hepatic lobes, causing
impairment of the afferent and efferent circulation. The
technique involves initial completion of parenchymal
dissection before the right lobe is mobilized. Belghiti
et al. described a promising modification of this tech-
nique, using a tape introduced under the anterior surface
of the IVC to ‘hang’ the liver and resulting in a safe ap-
proach to right hepatectomy without liver mobilization
[29]. The anatomical basis of this ‘hanging maneuver’
has been thoroughly evaluated [30,31] and it has even
been proposed to be safe in a modified approach for left
hepatectomy by Suh et al. [32]. Previously, the advantage
of the anterior over the conventional approach has been
documented for the effects of tumor cell dissemination
by Liu et al. in patients suffering from hepatocellular
carcinoma [33]. Thus, according to the long established
‘no-touch’ philosophy, as little manipulation as possible
seems a logical step also in oncologic liver surgery. In
the presented study ‘non-conventional’ extended veno-
venous bypass liver surgery was needed for oncological
and safety reasons. Although one could argue that indi-
cations for in, ex, and ante situ techniques are rare,
there is a small group of patients who could benefit from
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[34-36]. When a veno-venous bypass is used, leukocyte
filters can be easily integrated.
Conclusions
In summary, this study clearly showed that intra-
operative filtration of potential malignant cells is tech-
nically feasible. Due to these results, further clinical
studies are justified. This also may help correlate prog-
nostic value and patient survival. Further differentiated
information by closer characterization of entrapped and
eventually passed tumor cells is needed, as well as the
development of more differentiated surgical techniques
using filtration technology. Combining filter systems
with new surgical techniques requiring less manipulation
and molecular target therapy against circulating tumor
cells seems an especially promising approach to reduce
tumor recurrence after liver resection.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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